{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T08:02:32Z","timestamp":1775116952032,"version":"3.50.1"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2012,1,26]],"date-time":"2012-01-26T00:00:00Z","timestamp":1327536000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100001316","name":"Abbott Laboratories","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007313","name":"MD Anderson's Cancer Center Support","doi-asserted-by":"publisher","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}],"id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose.<\/jats:title>\n                  <jats:p>Premature ovarian failure occurs in 40%\u201370% of patients who receive conventional chemotherapy alone. However, the incidence is higher, 70%\u2013100%, in patients who undergo myeloablative chemotherapy with hematopoietic stem cell transplantation (HSCT). Gonadotropin-releasing hormone (GnRH) analogs, such as leuprolide, in a continuous-release formulation, may protect the ovaries from the gonadotoxic effects of chemotherapy. In non-HSCT settings, GnRH analogs have reduced the risk for premature ovarian failure to &amp;lt;10%. We conducted a phase II clinical trial based on the hypothesis that giving leuprolide before conditioning chemotherapy in HSCT patients reduces premature ovarian failure incidence.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and Methods.<\/jats:title>\n                  <jats:p>Eligible patients were women aged \u226440 years who were HSCT candidates, were premenopausal, and had both follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels \u226420 IU\/L. Two 22.5-mg leuprolide doses were delivered in 3-month depot i.m. injections, the first within 2 months before HSCT. Patients were monitored for menstruation return, and ovarian function tests (FSH, LH, and estradiol) were done every 2 months starting 90 days after the last leuprolide dose.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results.<\/jats:title>\n                  <jats:p>Sixty eligible patients were enrolled, 59 underwent HSCT, and 44 were evaluable (median age, 25 years; median follow-up, 355 days). Only seven of 44 patients (16%) regained ovarian function. Of the 33 who received myeloablative regimens, six (18%) regained ovarian function. However, among the 11 who received nonmyeloablative regimens, only one (9%) regained ovarian function (p = .66).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion.<\/jats:title>\n                  <jats:p>Leuprolide did not preserve ovarian function in patients who underwent HSCT using either myeloablative or nonmyeloablative regimens. Other measures that protect ovarian function need to be investigated.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2011-0205","type":"journal-article","created":{"date-parts":[[2012,1,27]],"date-time":"2012-01-27T03:11:33Z","timestamp":1327633893000},"page":"233-238","source":"Crossref","is-referenced-by-count":26,"title":["Phase II Study of Gonadotropin-Releasing Hormone Analog for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients"],"prefix":"10.1093","volume":"17","author":[{"given":"Yee Chung","family":"Cheng","sequence":"first","affiliation":[{"name":"a Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA;"},{"name":"c Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariko","family":"Takagi","sequence":"additional","affiliation":[{"name":"c Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Milbourne","sequence":"additional","affiliation":[{"name":"b Departments of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard E.","family":"Champlin","sequence":"additional","affiliation":[{"name":"c Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoto T.","family":"Ueno","sequence":"additional","affiliation":[{"name":"c Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2012,1,26]]},"reference":[{"key":"2021122308120175800_B1","first-page":"1527","article-title":"Quality of life of long-term adult survivors of autologous bone marrow transplantation","volume":"22","author":"Whedon","year":"1995","journal-title":"Oncol Nurs Forum"},{"key":"2021122308120175800_B2","first-page":"579","article-title":"Quality of life in breast cancer patients before and after autologous bone marrow transplantation","volume":"18","author":"McQuellon","year":"1996","journal-title":"Bone Marrow Transplant"},{"issue":"suppl 2","key":"2021122308120175800_B3","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1038\/sj.bmt.1702864","article-title":"Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation","volume":"27","author":"Champlin","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"2021122308120175800_B4","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1200\/JCO.2006.06.5888","article-title":"American Society of Clinical Oncology recommendations on fertility preservation in cancer patients","volume":"24","author":"Lee","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122308120175800_B5","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/1097-0142(19890801)64:3<641::AID-CNCR2820640313>3.0.CO;2-0","article-title":"Long-term endocrine toxicity of myeloablative treatment followed by autologous bone marrow\/blood derived stem cell transplantation in patients with malignant lymphohematopoietic disorders","volume":"64","author":"Keilholz","year":"1989","journal-title":"Cancer"},{"key":"2021122308120175800_B6","first-page":"511","article-title":"Prospective study of pituitary-gonadal function to evaluate short-term effects of ablative chemotherapy or total body irradiation with autologous or allogenic marrow transplantation in post-menarcheal female patients","volume":"13","author":"Chatterjee","year":"1994","journal-title":"Bone Marrow Transplant"},{"key":"2021122308120175800_B7","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/sj.bmt.1702695","article-title":"Reproductive status in long-term bone marrow transplant survivors receiving busulfan-cyclophosphamide (120 mg\/kg)","volume":"26","author":"Grigg","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"2021122308120175800_B8","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1182\/blood.V87.7.3045.bloodjournal8773045","article-title":"Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation","volume":"87","author":"Sanders","year":"1996","journal-title":"Blood"},{"key":"2021122308120175800_B9","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0959-8049(97)10036-3","article-title":"Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: Results of the International Breast Cancer Study Group (IBCSG) Trial VI","volume":"34","author":"Pagani","year":"1998","journal-title":"Eur J Cancer"},{"key":"2021122308120175800_B10","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0959-8049(99)00225-7","article-title":"Prognostic effect of amenorrhoea and elevated serum gonadotropin levels induced by adjuvant chemotherapy in premenopausal node-positive breast cancer patients","volume":"36","author":"Poikonen","year":"2000","journal-title":"Eur J Cancer"},{"key":"2021122308120175800_B11","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1002\/1097-0142(19830915)52:6<988::AID-CNCR2820520610>3.0.CO;2-6","article-title":"The effect of combination chemotherapy on ovarian function in women treated for Hodgkin's disease","volume":"52","author":"Whitehead","year":"1983","journal-title":"Cancer"},{"key":"2021122308120175800_B12","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/978-1-4615-0919-6_7","article-title":"Non-myeloablative allogeneic hematopoietic transplantation and induction of graft-versus-malignancy","volume":"110","author":"Khouri","year":"2002","journal-title":"Cancer Treat Res"},{"key":"2021122308120175800_B13","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1530\/acta.0.1210055","article-title":"Gonadotropin-releasing hormone agonist inhibits physiologic ovarian follicular loss in rats","volume":"121","author":"Ataya","year":"1989","journal-title":"Acta Endocrinol (Copenh)"},{"key":"2021122308120175800_B14","first-page":"3651","article-title":"A luteinizing hormone-releasing hormone agonist for the prevention of chemotherapy-induced ovarian follicular loss in rats","volume":"45","author":"Ataya","year":"1985","journal-title":"Cancer Res"},{"key":"2021122308120175800_B15","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1001\/archinte.1956.00250210045003","article-title":"Treatment of chronic granulocytic leukemia with myleran","volume":"97","author":"Louis","year":"1956","journal-title":"AMA Arch Intern Med"},{"key":"2021122308120175800_B16","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/j.1749-6632.1958.tb42652.x","article-title":"Busulfan (1, 4-dimethanesulfonyloxybutane, myleran): Summary of clinical results","volume":"68","author":"Galton","year":"1958","journal-title":"Ann N Y Acad Sci"},{"key":"2021122308120175800_B17","first-page":"397","article-title":"Comments on the development of amenorrhoea caused by myeleran in cases of chronic myelosis","volume":"7","author":"Belohorsky","year":"1960","journal-title":"Neoplasma"},{"key":"2021122308120175800_B18","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1002\/1097-0142(197704)39:4<1403::AID-CNCR2820390408>3.0.CO;2-8","article-title":"Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer","volume":"39","author":"Koyama","year":"1977","journal-title":"Cancer"},{"key":"2021122308120175800_B19","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/art.1780110205","article-title":"Long-term cyclophosphamide therapy in rheumatoid arthritis","volume":"11","author":"Fosdick","year":"1968","journal-title":"Arthritis Rheum"},{"key":"2021122308120175800_B20","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0140-6736(72)90502-8","article-title":"Sterility and cyclophosphamide","volume":"1","author":"Uldall","year":"1972","journal-title":"Lancet"},{"key":"2021122308120175800_B21","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1056\/NEJM197311292892202","article-title":"Cyclophosphamide-induced ovarian failure","volume":"289","author":"Warne","year":"1973","journal-title":"N Engl J Med"},{"key":"2021122308120175800_B22","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/S0140-6736(87)90606-4","article-title":"Ovarian failure after high-dose melphalan in adolescents","volume":"1","author":"Kellie","year":"1987","journal-title":"Lancet"},{"key":"2021122308120175800_B23","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1200\/JCO.1996.14.5.1718","article-title":"Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer","volume":"14","author":"Bines","year":"1996","journal-title":"J Clin Oncol"},{"key":"2021122308120175800_B24","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1093\/oxfordjournals.humrep.a137985","article-title":"Ultrastructure of human ovarian primordial follicles after combination chemotherapy for Hodgkin's disease","volume":"8","author":"Familiari","year":"1993","journal-title":"Hum Reprod"},{"key":"2021122308120175800_B25","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/bjc.1978.166","article-title":"Morphological study of the ovaries of leukaemic children","volume":"38","author":"Himelstein-Braw","year":"1978","journal-title":"Br J Cancer"},{"key":"2021122308120175800_B26","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3181\/00379727-133-34438","article-title":"Changes in mouse ovaries after prolonged treatment with cyclophosphamide","volume":"133","author":"Miller","year":"1970","journal-title":"Proc Soc Exp Biol Med"},{"key":"2021122308120175800_B27","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/0039-128X(89)90084-6","article-title":"Chemotherapy-induced premature ovarian failure: Mechanisms and prevention","volume":"54","author":"Ataya","year":"1989","journal-title":"Steroids"},{"key":"2021122308120175800_B28","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/sj.bmt.1701483","article-title":"Ovarian function after autologous bone marrow transplantation in childhood: High-dose busulfan is a major cause of ovarian failure","volume":"22","author":"Teinturier","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"2021122308120175800_B29","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/sj.bmt.1701075","article-title":"Ovarian function after bone marrow transplantation during childhood","volume":"21","author":"Thibaud","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"2021122308120175800_B30","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1093\/oxfordjournals.humrep.a019457","article-title":"Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotrophin-releasing hormone agonist in parallel to chemotherapy","volume":"11","author":"Blumenfeld","year":"1996","journal-title":"Hum Reprod"},{"key":"2021122308120175800_B31","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1006\/gyno.2001.6181","article-title":"Use of GnRH analogs for functional protection of the ovary and preservation of fertility during cancer treatment in adolescents: A preliminary report","volume":"81","author":"Pereyra Pacheco","year":"2001","journal-title":"Gynecol Oncol"},{"key":"2021122308120175800_B32","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.fertnstert.2007.12.044","article-title":"Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: Prospective randomized study","volume":"91","author":"Badawy","year":"2009","journal-title":"Fertil Steril"},{"key":"2021122308120175800_B33","first-page":"269","article-title":"Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: A randomized trial","volume":"306","author":"Del Mastro","year":"2011","journal-title":"JAMA"},{"key":"2021122308120175800_B34","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1089\/jwh.2008.0857","article-title":"Ovarian preservation by GnRH agonists during chemotherapy: A meta-analysis","volume":"18","author":"Clowse","year":"2009","journal-title":"J Womens Health (Larchmt)"},{"key":"2021122308120175800_B35","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/BF00254570","article-title":"Failure to preserve fertility in patients with Hodgkin's disease","volume":"19","author":"Waxman","year":"1987","journal-title":"Cancer Chemother Pharmacol"},{"key":"2021122308120175800_B36","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s10815-008-9276-4","article-title":"Assessment of ovarian reserve following ovarian tissue banking and\/or GnRH-a co-treatment prior to chemotherapy in patients with Hodgkin's disease","volume":"25","author":"Azem","year":"2008","journal-title":"J Assist Reprod Genet"},{"key":"2021122308120175800_B37","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/humupd\/dmh021","article-title":"Fertility preservation in female patients","volume":"10","author":"Sonmezer","year":"2004","journal-title":"Hum Reprod Update"},{"key":"2021122308120175800_B38","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/j.bbmt.2009.07.019","article-title":"Receiving information on fertility- and menopause-related treatment effects among women who undergo hematopoietic stem cell transplantation: Changes in perceived importance over time","volume":"15","author":"Nakayama","year":"2009","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2011-0205","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2011-0205","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/17\/2\/233\/41860252\/oncolo_17_2_233.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/17\/2\/233\/41860252\/oncolo_17_2_233.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T19:37:10Z","timestamp":1640288230000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/17\/2\/233\/6403292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,26]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2012,1,26]]},"published-print":{"date-parts":[[2012,2,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2011-0205","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2012,2,1]]},"published":{"date-parts":[[2012,1,26]]}}}